What the Research Shows Recent research on semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has revealed concerning trends about body composition changes: A 2023 analysis of STEP trial data found that approximately 39% of weight lost on semaglutide was lean body mass 1 Research on tirzepatide showed similar patterns, with 30-40% of total weight loss coming from lean tissue 2 Comparative studies indicate GLP-1 users may lose more muscle than people losing weight through diet and exercise alone 3 For context: if you lose 50 pounds on a GLP-1 medication, 15-20 pounds might be muscle mass
Medical Conditions: If you have inflammatory bowel disease, celiac disease, or other gut disorders, consult a healthcare provider before making significant dietary changes
The label advises two capsules per day with water, ideally before a main meal
Liraglutide is a previous generation GLP-1 and future studies will use more powerful current generation therapies like semaglutide or tirzepatide
Lousse JC, Defrre S, Van Langendonckt A, Gras J, Gonzlez-Ramos R, Colette S, et al
He placed sixth in the 2013 Mr